BMO Capital Reiterates Outperform on Eli Lilly (LLY) After Self Pay Program Expansion

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,010.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented: "Lilly's self pay program is expanded with a new offering of 7.5mg and 10mg single-use vials through LillyDirect. 2.5mg and 5mg single-use vials have also been reduced to $349 and $499 per month through the self pay system, potentially further incentivizing demand for cash pay patients without significant insurance coverage. We view today's decision to expand the self pay offering as a mild positive for LLY shares as we expect the company will continue to be able to realize higher net revenue per script for cash pay patients using LillyDirect."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $901.80 yesterday.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Morgan Stanley Upgrades Oil India Ltd. (OINL:IN) to Equalweight
• Kepler Cheuvreux Downgrades Carl Zeiss Meditec AG (AFXG:GR) (CZMWY) to Reduce